Phagos
Category: AI in Biotech / Drug Discovery
AI-powered phage therapies to combat antibiotic resistance in animals. Phagos was founded in 2021. The company is led by Alexandros Pantalis. Based in Suresnes, France. Team size: 11-50. Total funding raised: €27.4 million. Latest round: Series A, €25.0M, 2025-10, led by CapAgro, Hoxton Ventures, CapHorn, and Demeter. Key investors include CapAgro, Hoxton Ventures, CapHorn, Demeter, Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, Station F.
- Founded
- 2021
- Headquarters
- Suresnes, France
- Team size
- 11-50
- Total funding
- €27.4 million
Value proposition
Provides a rapid (2-month development cycle) and sustainable alternative to antibiotics, offering personalized treatments against resistant bacteria.
Products and solutions
Custom bacteriophage solutions, AI-driven phage discovery platform
Unique value
The use of a proprietary AI platform to analyze a vast library of bacteriophages and rapidly develop highly targeted treatments against specific bacterial infections.
Target customer
Veterinary and aquaculture sectors, specifically chicken, cattle, swine, and shrimp farms.
Industries served
Animal Health, Veterinary, Aquaculture
Technology advantage
Their AI-powered platform significantly accelerates the discovery and development of personalized phage therapies, enabling a much faster response to emerging bacterial threats compared to traditional methods.
How they differentiate
Phagos differentiates itself by using a proprietary AI platform to develop personalized phage therapies that serve as a sustainable alternative to antibiotics in animal health. This AI-driven approach allows them to create targeted treatments for bacterial diseases in just two months.
Main competitors
Proteon Pharmaceuticals, Cytophage Technologies, Vetophage
Key partnerships
Amazon Web Services (AWS)
Notable customers
While specific names are not public, Phagos targets chicken, cattle, swine, and shrimp farms.
Major milestones
First EU authorization to market personalized veterinary phage drugs (ANMV, ~2025)., €25M Series A (Oct 2025) co-led by CapAgro, Hoxton Ventures, CapHorn, Demeter., €2.4M seed (2022)., Laureate of France 2030 Pionniers de l'IA for PRESAGES generative phage-genome AI (Jun 2026)., Tech for Future 2026 Santé prize (La Tribune/BFM)., >1M animals treated; Alphagos AI platform on AWS.
Growth metrics
Official site (Jul 2026): ~50 employees, >1M animals treated, 11 clinical trials; LinkedIn people graph ~75; ~66% YoY headcount growth (Crustdata Jul 2026).
Market positioning
Phagos is positioned as a biotechnology company at the intersection of AI and phage therapy, focusing on the veterinary market. They aim to combat antibiotic resistance in animal agriculture by providing a rapid, personalized, and sustainable solution.
Geographic focus
While Phagos is based in Paris, France, their focus is global. They serve chicken, cattle, swine, and shrimp farms worldwide, with the recent funding intended to accelerate their global expansion.
Patents and IP
The company has a patented AI technology for phage discovery.
About Alexandros Pantalis
Co-founder and CEO of Phagos. Master's in Management from HEC Paris; previously cofounded multiple tech startups and worked at EY. Founder in Residence at Entrepreneur First before founding Phagos to tackle antibiotic resistance.
Latest news about Phagos
More AI in Biotech / Drug Discovery companies
Official website: https://phagos.com